Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Takeda and Dimerix agree GPCR research partnership

Takeda and Dimerix agree GPCR research partnership

22nd April 2010

Takeda Cambridge has agreed a new research collaboration with pre-clinical stage product specialist Dimerix Bioscience, which will focus on the study of G-protein coupled receptors (GPCRs).

The agreement will see Dimerix utilise its GPCR Heteromer Identification Technology (GPCR-HIT) to research certain compounds identified by Takeda, with the aim of creating specialised drugs.

GPCR-HIT allows for a range of potential GPCR research capabilities, such as profiling for potential toxicity or identifying side effects of compounds.

Tim Grogan, chief executive officer of Dimerix, said the collaboration will help Takeda to develop “more specific drugs that take into account the signalling profile of GPCRs acting in heteromeric complexes”.

Mark Carlton, president of Takeda Cambridge, added: “This work will continue to build on our knowledge of key GPCRs, which are drug targets of major significance.”

Earlier this month, Takeda commenced a phase III clinical trial of its Hodgkin’s lymphoma drug brentuximab vedotin, which has been developed in conjunction with Millennium and Seattle Genetics.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.